ArticleFrontiers in psychiatry2025
The Bipolar Disorder Medication Adherence Battery: validity, reliability, and clinical benchmarks.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication adherence is pivotal in bipolar disorder, yet no tools assess the full range of psychological and contextual determinants that translate intention into behavior. This study developed and validated the Bipolar Disorder Medication Adherence Battery (BD-MAB) to support routine, measurement-based care. Methods: The analytic sample comprised 167 adults with DSM-5 bipolar I disorder recruited from outpatient and inpatient services at a tertiary psychiatric hospital. Guided by the Integrated Behavioral Model, we mapped process measures-Attitude; Perceived norms (supportive, oppositional, pressuring, descriptive); Perceived control; Self-efficacy; Knowledge and skills; Environmental Constraints; Salience of Behavior; Habit; Intention and a behavior indicator. Psychometrics included internal consistency; construct validity via inter-construct correlations; convergent and discriminant validity with the Medication Adherence Rating Scale, Medication Adherence Report Scale, perceived social support, and quality of life; criterion validity against same-day serum medication levels; and distribution-based thresholds (standard error of measurement, critical change, minimally important difference, reliable change index). Results: Administered to euthymic adults with bipolar I disorder receiving mood stabilizers at a tertiary psychiatric hospital, the BD-MAB showed acceptable to excellent internal consistency across multi-item scales. Relations among constructs were theory-consistent, with intention aligning most closely with self-efficacy and attitudes, and the behavior indicator tracking intention. Concordance with serum levels supported criterion validity, and associations with an established adherence measure supported convergent validity. Clinically interpretable thresholds were derived to flag meaningful change for use in routine care. Conclusions: The BD-MAB offers a comprehensive, clinically actionable assessment of adherence determinants and behavior in bipolar disorder, with initial evidence for reliability, validity, and practical change metrics to guide patient-level monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.